Curanex Total Other Income Expense Net from 2010 to 2026
| CURX Stock | 0.30 0.02 7.14% |
Total Other Income Expense Net | First Reported 2010-12-31 | Previous Quarter 4.1 K | Current Value 4.3 K | Quarterly Volatility 1.5 K |
Check Curanex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Curanex Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 K, Selling General Administrative of 350.6 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 5.2 K, Dividend Yield of 0.0 or PTB Ratio of 242. Curanex financial statements analysis is a perfect complement when working with Curanex Pharmaceuticals Valuation or Volatility modules.
Curanex | Total Other Income Expense Net | Build AI portfolio with Curanex Stock |
The evolution of Total Other Income Expense Net for Curanex Pharmaceuticals Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Curanex Pharmaceuticals compares to historical norms and industry peers.
Latest Curanex Pharmaceuticals' Total Other Income Expense Net Growth Pattern
Below is the plot of the Total Other Income Expense Net of Curanex Pharmaceuticals Common over the last few years. It is Curanex Pharmaceuticals' Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Curanex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Total Other Income Expense Net | 10 Years Trend |
|
Total Other Income Expense Net |
| Timeline |
Curanex Total Other Income Expense Net Regression Statistics
| Arithmetic Mean | 784.66 | |
| Geometric Mean | 191.46 | |
| Coefficient Of Variation | 195.05 | |
| Mean Deviation | 1,128 | |
| Median | 100.00 | |
| Standard Deviation | 1,530 | |
| Sample Variance | 2.3M | |
| Range | 4.2K | |
| R-Value | 0.66 | |
| Mean Square Error | 1.4M | |
| R-Squared | 0.44 | |
| Significance | 0 | |
| Slope | 201.50 | |
| Total Sum of Squares | 37.5M |
Curanex Total Other Income Expense Net History
About Curanex Pharmaceuticals Financial Statements
Curanex Pharmaceuticals investors use historical fundamental indicators, such as Curanex Pharmaceuticals' Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Curanex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Other Income Expense Net | 4.1 K | 4.3 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Curanex Stock Analysis
When running Curanex Pharmaceuticals' price analysis, check to measure Curanex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curanex Pharmaceuticals is operating at the current time. Most of Curanex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Curanex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curanex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Curanex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.